Philippe ROCHIGNEUX

Identifiants chercheurs

IdHAL :

philippe-rochigneux

ORCID :

0000-0001-7932-0530

IdRef :

159209404

ResearcherID :

ABE-7247-2020

Présentation

Publications

Article dans une revue (31)

Vγ9Vδ2 T Cells Express an Antitumor Profile Associated with Anti–PD-(L)1 Responses and Activation Defects Restored by Anti-BTN3A in Triple-Negative Breast Cancer Stéphane Fattori,Laurent Gorvel,Marie-Sarah Rouviére,Samuel Granjeaud,Amira Ben Amaraet al. Cancer Immunology Research, 2025, 13 (10), pp.1623-1639. ⟨10.1158/2326-6066.CIR-24-1285⟩ Article dans une revue hal-05555456v1
Case report: A severe myositis mimicking bulbar palsy after administration of immune checkpoint inhibitors Philippe Rochigneux,Alexandre Bertucci,Elika Loir,Alexia Mattei,Danielle Robertet al. Frontiers in Immunology, 2025, 16, ⟨10.3389/fimmu.2025.1496427⟩ Article dans une revue hal-05578016v1
Facial palsy after administration of immune checkpoint inhibitors: case report, literature review and clinical care management Essia Mezni,Giovanni Corazza,Roxane Mari,Stephanie Coze,Nathalie Charrieret al. Frontiers in Immunology, 2024, 15, ⟨10.3389/fimmu.2024.1375497⟩ Article dans une revue hal-05141525v1
Impact of fiducial markers placement on the delineation of target volumes in radiation therapy for oesophageal cancer: FIDUCOR study Philippe Rochigneux,Marguerite Tyran,Aurélie Autret,Leonor Lopez Almeida,Jérôme Guiramandet al. Frontiers in Oncology, 2022, 12, ⟨10.3389/fonc.2022.1012712⟩ Article dans une revue hal-03869102v1
Immunotherapy in MSI/dMMR tumors in the perioperative setting: The IMHOTEP trial Clélia Coutzac,Frédéric Bibeau,Méher Ben Abdelghani,Thomas Aparicio,Romain Cohenet al. Digestive and Liver Disease, 2022, 54 (10), pp.1335-1341. ⟨10.1016/j.dld.2022.07.008⟩ Article dans une revue hal-03837196v1
Soluble BTN2A1 Is a Potential Prognosis Biomarker in Pre-Treated Advanced Renal Cell Carcinoma Emilien Billon,Brice Chanez,Philippe Rochigneux,Laurence Albiges,Cécile Vicieret al. Frontiers in Immunology, 2021, 12, ⟨10.3389/fimmu.2021.670827⟩ Article dans une revue hal-03623028v1
High-dimensional mass cytometry analysis of NK cell alterations in AML identifies a subgroup with adverse clinical outcome Anne-Sophie Chretien,Raynier Devillier,Samuel Granjeaud,Charlotte Cordier,Clemence Demerleet al. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118 (22), pp.e2020459118. ⟨10.1073/pnas.2020459118⟩ Article dans une revue hal-03565991v1
Endometrial Carcinoma: Immune Microenvironment and Emerging Treatments in Immuno-Oncology Sandrine Rousset-Rouviere,Philippe Rochigneux,Anne-Sophie Chrétien,Stéphane Fattori,Laurent Gorvelet al. Biomedicines, 2021, 9 (6), pp.632. ⟨10.3390/biomedicines9060632⟩ Article dans une revue hal-03622756v1
Quantification of Immune Variables from Liquid Biopsy in Breast Cancer Patients Links Vδ2+ γδ T Cell Alterations with Lymph Node Invasion Stéphane Fattori,Laurent Gorvel,Samuel Granjeaud,Philippe Rochigneux,Marie-Sarah Rouvièreet al. Cancers, 2021, 13 (3), pp.441. ⟨10.3390/cancers13030441⟩ Article dans une revue hal-03152759v1
739P Efficacy and safety of maintenance olaparib and bevacizumab (bev) in ovarian cancer (OC) patients (pts) aged ≥65 years (y) from the PAOLA-1/ENGOT-ov25 first-line trial Renaud Sabatier,Cécile Vicier,Séverine Garnier,Arnaud Guille,Nadine Carbucciaet al. Annals of Oncology, 2021, 32 (15_suppl), pp.S737-S738. ⟨10.1016/j.annonc.2021.08.1181⟩ Article dans une revue hal-03622737v1
Immune checkpoint inhibitor induced thyroid dysfunction is a frequent event post-treatment in NSCLC Nanruoyi Zhou,Maria Velez,Benjamin Bachrach,Jaklin Gukasyan,Charlene Fareset al. Lung Cancer, 2021, 161, pp.34-41. ⟨10.1016/j.lungcan.2021.08.009⟩ Article dans une revue hal-03689919v1
Adoptive Cell Therapy in Hepatocellular Carcinoma: Biological Rationale and First Results in Early Phase Clinical Trials Philippe Rochigneux,Brice Chanez,Bernadette de Rauglaudre,Emmanuel Mitry,Christian Chabannonet al. Cancers, 2021, 13 (2), pp.271. ⟨10.3390/cancers13020271⟩ Article dans une revue hal-03689931v1
Celiac Disease After Administration of Immune Checkpoint Inhibitors: A Case Report Julie Leblanc,Solene Hoibian,Agathe Boucraut,Jean-Philippe Ratone,Louis Stoffaeset al. Frontiers in Immunology, 2021, 12, ⟨10.3389/fimmu.2021.799666⟩ Article dans une revue hal-03689905v1
Endoscopic Ultrasound-Guided Radiofrequency Ablation as an Future Alternative to Pancreatectomy for Pancreatic Metastases from Renal Cell Carcinoma: A Prospective Study Brice Chanez,Fabrice Caillol,Jean-Philippe Ratone,Christian Pesenti,Philippe Rochigneuxet al. Cancers, 2021, 13 (21), pp.5267. ⟨10.3390/cancers13215267⟩ Article dans une revue hal-03689914v1
Les glycosylations de PD-L1 sous les feux de la rampe Daniel Olive,Anne-Sophie Chrétien,Raynier Devillier,Philippe Rochigneux,Laurent Gorvelet al. Médecine/Sciences, 2020, 36 (6-7), pp.552-555. ⟨10.1051/medsci/2020099⟩ Article dans une revue hal-02903988v1
Medical Treatment of Lung Cancer: Can Immune Cells Predict the Response? A Systematic Review Philippe Rochigneux,Alejandro Garcia,Brice Chanez,Anne Madroszyk,Daniel Oliveet al. Frontiers in Immunology, 2020, 11, ⟨10.3389/fimmu.2020.01036⟩ Article dans une revue hal-03152719v1
PD-1/PD-L1 Targeting in Breast Cancer: The First Clinical Evidences Are Emerging. A Literature Review Gabrielle Planes-Laine,Philippe Rochigneux,François Bertucci,Anne-Sophie Chrétien,Patrice Vienset al. Cancers, 2019, 11 (7), pp.1033. ⟨10.3390/cancers11071033⟩ Article dans une revue (article de synthèse) hal-02533030v1
Long-term efficacy of crizotinib in a metastatic papillary renal carcinoma with MET amplification: a case report and literature review Philippe Rochigneux,Jeanne Thomassin-Piana,Sophy Laibe,Serge Brunelle,Naji Salemet al. BMC Cancer, 2018, 18 (1), pp.1159. ⟨10.1186/s12885-018-5049-3⟩ Article dans une revue hal-03689938v1
Are lung adenocarcinoma mutations shaping the immune microenvironment? Philippe Rochigneux,Edward B. Garon Translational Cancer Research, 2018, 7 (7), pp.S740-S742. ⟨10.21037/tcr.2018.07.17⟩ Article dans une revue hal-02143662v1
Dynamic of systemic immunity and its impact on tumor recurrence after radiofrequency ablation of hepatocellular carcinoma Philippe Rochigneux,Jean-Charles Nault,Françoise Mallet,Anne-Sophie Chretien,Nathalie Bargetet al. Annals of Oncology, 2018, 29 (10), pp.7. ⟨10.1080/2162402X.2019.1615818⟩ Article dans une revue hal-02143627v1
Timing of palliative care needs reporting and aggressiveness of care near the end of life in metastatic lung cancer: A national registry-based study François Goldwasser,Pascale Vinant,Régis Aubry,Philippe Rochigneux,Yvan Beaussantet al. Cancer, 2018, 124 (14), pp.3044-3051. ⟨10.1002/cncr.31536⟩ Article dans une revue hal-03689951v1
Hyperprogressive Disease in Anorectal Melanoma Treated by PD-1 Inhibitors Marjorie Faure,Philippe Rochigneux,Daniel Olive,Sebastien Taix,Isabelle Brenot-Rossiet al. Frontiers in Immunology, 2018, 9, ⟨10.3389/fimmu.2018.00797⟩ Article dans une revue hal-02143544v1
Hospital end-of-life care in haematological malignancies Yvan Beaussant,Etienne Daguindau,Adrien Chauchet,Philippe Rochigneux,Christophe Tournigandet al. BMJ Palliative and supportive care, 2018, 8 (3), pp.314-324. ⟨10.1136/bmjspcare-2017-001446⟩ Article dans une revue hal-03689944v1
Acute myositis Philippe Rochigneux,Nicolas Schleinitz,Mikael Ebbo,Marie Aymonier,Bertrand Pourroyet al. Anti-Cancer Drugs, 2018, 29 (5), pp.477-481. ⟨10.1097/CAD.0000000000000620⟩ Article dans une revue hal-03689955v1
Long-term efficacy of crizotinib in a metastatic papillary renal carcinoma with MET amplification: a case report and literature review Philippe Rochigneux,Jeanne Thomassin-Piana,Sophy Laibe,Serge Brunelle,Naji Salemet al. BMC Cancer, 2018, 18 (1), pp.1159. ⟨10.1186/s12885-018-5049-3⟩ Article dans une revue hal-04515988v1
Gastrointestinal Stromal Tumour with Synchronous Bone Metastases: A Case Report and Literature Review Philippe Rochigneux,Lénaig Mescam-Mancini,Delphine Perrot,Erwan Bories,Laurence Moureau-Zabottoet al. Case Reports in Oncology, 2017, 10 (1), pp.66-76. ⟨10.1159/000455188⟩ Article dans une revue hal-03623722v1
Quelle vision des biomarqueurs en 2017 ? Promesses et défis de la médecine personnalisée en oncologie Ronan Flippot,Christophe Massard,Édouard Auclin,David Azria,Heloise Bourienet al. Bulletin du Cancer, 2017, 104 (9), pp.735-743. ⟨10.1016/j.bulcan.2017.07.003⟩ Article dans une revue hal-02370054v1
Use of chemotherapy near the end of life: what factors matter? Philippe Rochigneux,J.L. Raoul,Y. Beaussant,R. Aubry,F. Goldwasseret al. Annals of Oncology, 2017, 28 (4), pp.809-817. ⟨10.1093/annonc/mdw654⟩ Article dans une revue hal-03689961v1
Discrepancies in the use of chemotherapy and artificial nutrition near the end of life for hospitalised patients with metastatic gastric or oesophageal cancer. A countrywide, register-based study Emmanuelle Kempf,Christophe Tournigand,Philippe Rochigneux,Régis Aubry,Lucas Morin European Journal of Cancer, 2017, 79, pp.31-40. ⟨10.1016/j.ejca.2017.03.029⟩ Article dans une revue istex hal-03560299v1
Les actualités marquantes du congrès Targeted Anticancer Therapies — TAT 2016 R. Flippot,I. Bouallagui,P. Du Rusquec,P. Gougis,C. Henonet al. Oncologie, 2016, 18 (7-8), pp.451-462. ⟨10.1007/s10269-016-2651-3⟩ Article dans une revue hal-03689977v1
End-of-life care for hospitalized patients with metastatic melanoma in France: a nationwide, register-based study I. Gallais Sérézal,Y. Beaussant,Philippe Rochigneux,C. Tournigand,R. Aubryet al. British Journal of Dermatology, 2016, 175 (3), pp.583-592. ⟨10.1111/bjd.14631⟩ Article dans une revue istex hal-03689969v1